Proteins and peptides in enteral nutrition;Proteínas y péptidos en nutrición enteral

Nutricion Hospitalaria

Volumn 21, Issue SUPPL. 2, 2006, Pages 1-14

  Martinez Augustin O ^a,c   Martinez De Victoria Munoz E ^b  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c s n   (Spain)

Author keywords

Amino acids; Bioactive peptides; Eggs; Functional proteins; Growth factors; Lactoferrin; Milk; PDCAAS; Protein complementation; Protein quality; Soy

Indexed keywords

IMMUNOGLOBULIN; NUTRACEUTICAL; PEPTIDE; PROTEIN; SOYBEAN PROTEIN; TRANSFERRIN;

ANTIBACTERIAL ACTIVITY; ANTICOAGULATION; ANTIHYPERTENSIVE ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BIOAVAILABILITY; BIOLOGICAL ACTIVITY; CARDIOVASCULAR SYSTEM; EGG; ENTERIC FEEDING; FOOD HANDLING; FOOD PROCESSING; FUNCTIONAL FOOD; GASTROINTESTINAL TRACT; GLYCOSYLATION; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; MILK; NONHUMAN; PROTEIN INTAKE; PROTEIN QUALITY; PROTEIN STRUCTURE; REVIEW; SOYBEAN;

ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; DIETARY PROTEINS; DIGESTIVE SYSTEM; ENTERAL NUTRITION; FOOD ANALYSIS; HUMANS; IMMUNOLOGIC FACTORS; PEPTIDES;

EID: 33744935021     PISSN: 02121611     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Gil A (ed.): Tratado de nutrición. Tomo 1. Bases fisiológicas y bioquímicas de la nutrición. Acción Médica. Madrid, 2005.
2. Millward DJ, Jackson AA: Protein/energy ratios of current diets in developed and developing countries compared with a safe protein/energy ratio: implications for recommended protein and amino acid intakes. Public Health Nutrition 2003; 7:387-405.
3. Millward DJ: Macronutrient Intakes as Determinants of Dietary Protein and Amino Acid Adequacy. J Nutr 2004; 134:1588S-1596S.
4. Reeds PJ: Dispensable and Indispensable Amino Acids for Humans. J Nutr 2000; 130:1835S-1840S.
5. Reeds PJ, Garlick PJ: Protein and Amino Acid Requirements and the Composition of Complementary Foods. J Nutr 2003; 133:2953S-2961S.
6. Malcolm F, Fuller MF, Tomé D: In vivo Determination of Amino Acid Bioavailability in Humans and Model Animals. J AOAC Int 2005; 88:923-934.
7. Darragh AJ, Hodgkinson SM: Quantifying the Digestibility of Dietary Protein. J Nutr 2000; 130:1850S-1856S.
8. FAO/WHO Expert Consultation. Protein Quality Evaluation. Food and Agricultural Organization of the United Nations, FAO Food and Nutrition Paper 51. 1990. Rome.
9. FAO/WHO/UNU Expert Consultation. Energy and Protein Requirements. Technical Report Series 724. World Health Organization. 1985. Geneva.
10. Young VR Borgonha S: Nitrogen and Amino Acid Requirements: the Massachusetts Institute of Technology Amino Acid Requirement Pattern. J Nutr 130:1841S-1849S.
11. Schaafsma G: The Protein Digestibility-Corrected Amino Acid Score. J Nutr 2000; 130:1865S-1867S.
12. Mughan PJ: Dietary Protein Quality in Humans-An Overview. J AOAC Int 2005; 88:874-876.
13. Bos C, Gaudichon C, Tomé D: Nutritional and Physiological Criteria in the Assessment of Milk Protein Quality for Humans. Journal of the American College of Nutrition 2000; 19:191S-205S.
14. Meade SJ, Reid EA, Gerrard JA: The Impact of Processing on the Nutritional Quality of Food Proteins. J AOAC Int 2005; 88:904-922.
15. Gilani GS, Cockell KA, Sepehr E: Effects of Antinutritional Factors on Protein Digestibility and Amino Acid Availability in Foods. J AOAC Int 2005; 88:967-987.
16. Moughan PJ: Absorption of Chemically Unmodified Lysine from Proteins in Foods That Have Sustained Damage During Processing or Storage. J AOAC Int 2005; 88:949-954.
17. Finot PA: The Absorption and Metabolism of Modified Amino Acids in Processed Foods. J AOAC Int 2005; 88:894-903.
18. Sarwar G: The Protein Digestibility-Corrected Amino Acid Score Method Overestimates Quality of Proteins Containing Antinutritional Factors and of Poorly Digestible Proteins Supplemented with Limiting Amino Acids in Rats. J Nutr 1997; 127:758-764.
19. Gilani GS, Sepehr E: Protein Digestibility and Quality in Products Containing Antinutritional Factors Are Adversely Affected by Old Age in Rats. J Nutr 2003; 133:220-225.
20. Sánchez A, Scharffenberg JA, Register UD: Nutritive value of selected proteins and protein combinations. II Biological value predictability. Am J Clin Nut 1963; 13:250-253.
21. Schaafsma G: Nutritional appreciation of proteins. TNO Nutrition and Food Research Institute, Zeist, The Netherlands. 1994; 94:135.
22. Schaafsma G: The Protein Digestibility-Corrected Amino Acid Score (PDCAAS) -A Concept for Describing Protein Quality in Foods and Food Ingredients: a Critical Review. J AOAC Int 2005; 88:988-994.
23. Savoie L, Agudelo RA, Gauthier SF, Marin J, Pouliot Y: In vitro Determination of the Release Kinetics of Peptides and Free Amino Acids During the Digestion of Food Proteins. J AOAC Int 2005; 88:935-948.
24. Boirie Y, Dangin M, Gachon P, Vasson MP, Maubois JL, Beaufrere B: Slow and fast dietary proteins differently modulate postprandial protein accretion. Proc Natl Acad Sci USA 1997; 94:14930-14935.
25. Ball RO, Moehn S, Bertolo, RFP: Next Generation Diet Formulation: true Metabolic Availability of Amino Acids in Diets for Pigs. Advances in Pork Production 2004; 15:13.
26. Alison Darragh: Protein Effectiveness Index: a new method for expressing the value of dietary protein? 4th International Whey Conference. 2005. Chicago.
27. Burdock GA, Carabin IG, Griffiths JC: European regulations on nutraceuticals, dietary supplements and functional foods: a framework based on safety. Toxicology 2006. In press.
28. Bagchi D: Nutraceuticals and functional foods regulations in the United States and around the world. Toxicology 2006. In press.
29. Rutherfurd-Markwick KJ, Moughan PJ: Bioactive peptides derived from food. J AOAC Int 2005; 88:955-966.
30. Korhonen H, Pihlanto A: Food-derived bioactive peptidesopportunities for designing future foods. Curr Pharm Des 2003; 9:1297-1308.
31. Meisel H: Multifunctional peptides encrypted in milk proteins. Biofactors 2004; 21:55-61.
32. Teschemacher H, Koch G, Brantl V: Milk protein-dervied opioid receptor ligands. Biopoly 1997; 43:99-117.
33. Vermeirssen V, Van Camp J, Verstraete W: Bioavailability of angiotensin I converting enzyme inhibitory peptides. Br J Nutr 2004; 92:357-366.
34. Diehl-Jones WL, Askin DF: Nutritional modulation of neonatal outcomes. AACN Clin Issues 2004; 15:83-96.
35. Field CJ: The immunological components of human milk and their effect on immune development of infants. J Nutr 2005; 135:1-4.
36. Lonnerdal B: Nutritional and physiologic significance of human milk proteins. Am J Clin Nutr 2003; 77:1537S-1543S.
37. Fell JM: Control of systemic and local inflammation with transforming growth factor beta containing formulas. J Parenter Enteral Nutr 2005; 29:S126-S128.
38. Afzal NA, Van Der Zaag-Loonen HJ, Arnaud-Battandier F, Davies S, Murch S, Derkx B y cols.: Improvement in quality of life of children with acute Crohn's disease does not parallel mucosal healing after treatment with exclusive enteral nutrition. Aliment Pharmacol Ther 2004; 20:167-172.
39. Marshal K: Therapeutic applications of whey protein. Altern Med Rev 2004; 9:136-156.
40. Moreno YF, Sgarbieri VC, Da Silva MN, Toro A, Vilela MM: Features of Whey Protein Concentrate Supplementation in Children with Rapidly Progressive HIV Infection. J Trop Pediatr 2006; 52:34-38.
41. Micke P, Beeh KM, Buhl R: Effect of long-term suplemmentation wit whey proteins on plasma glutathione levels of HIV-infected patients. Eur J Nutr 2002; 41:12-18.
42. Micke P, Beeh KM, Schlaak JF, Buhl R: Oral supplementation with whey proteins increases plasma glutathione levels of HIV-infected patients. Eur J Clin Invest 2001; 31:171-178.
43. Farnaud S, Evans RW: Lactoferrin- a munifunctional protein with antimicrobial properties. Mol Immunol 2003; 40:395-405.
44. Orsi N: The antimicrobial activity of lactoferrin: current status and perspectives. Biometals 2004; 17:189-196.
45. Kovacs-Nolan J, Phillips M, Mine Y: Advances in the value of eggs and egg components for human health. J Agric Food Chem 2005; 53:8421-8431.
46. Okuda M, Nakazawa T, Yamauchi K y cols.: Bovine lactoferrin is effective to suppress Helicobacter pylori colonization in the human stomach: a randomized, double-blind, placebo-controlled study. J Infect Chemother 2005; 11:265-269.
47. Okada S, Tanaka K, Sato T, Ueno H, Saito S, Okusaka T y cols.: Dose-response trial of lactoferrin in patients with chronic hepatitis C. Jpn J Cancer Res 2002; 93:1063-1069.
48. Ishii K, Takamura N, Shinohara M, Wakui N, Shin H, Sumino Y y cols.: Long-term follow-up of chronic hepatitis C patients treated with oral lactoferrin for 12 months. Hepatol Res 2003; 25:226-233.
49. Giansanti F, Rossi P, Massucci MT, Botti D, Antonini G, Valenti P y cols.: Antiviral activity of ovotransferrin discloses an evolutionary strategy for the defensive activities of lactoferrin. Biochem Cell Biol 2002; 80:125-130.
50. Legrand D, Elass E, Pierce A, Mazurier J: Lactoferrin and host defence: an overview of its immuno-modulating and anti-inflammatory properties. Biometals 2004; 17:225-229.
51. Griffiths CE, Cumberbatch M, Tucker SC, Dearman RJ, Andrew S, Headon DR y cols.: Exogenous topical lactoferrin inhibits allergen-induced Langerhans cell migration and cutaneous inflammation in humans. Br J Dermatol 2001; 144:715-725.
52. Teraguchi S, Wakabayashi H, Kuwata H, Yamauchi K, Tamura Y: Protection against infections by oral lactoferrin: evaluation in animal models. Biometals 2004; 17:231-234.
53. Togawa J, Nagase H, Tanaka K, Inamori M, Nakajima A, Ueno N y cols.: Oral administration of lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance. J Gastroenterol Hepatol 2002; 17:1291-1298.
54. Togawa J, Nagase H, Tanaka K, Inamori M, Umezawa T, Nakajima A y cols.: Lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance. Am J Physiol Gastrointest Liver Physiol 2002; 283:G187-G195.
55. Thomassen EA, Van Veen HA, Van Berkel PH, Nuijens JH, Abrahams JP: The protein structure of recombinant human lactoferrin produced in the milk of transgenic cows closely matches the structure of human milk-derived lactoferrin. Transgenic Res 2005; 14:397-405.
56. Gifford JL, Hunter HN, Vogel HJ: Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cell Mol Life Sci 2005; 62:2588-2598.
57. Giansanti F, Massucci MT, Giardi MF, Nozza F, Pulsinelli E, Nicolini C y cols.: Antiviral activity of ovotransferrin derived peptides. Biochem Biophys Res Commun 2005; 331:69-73.
58. Asakura K, Kojima T, Shirasaki K y cols.: Evaluation of the effects of antigen specific immunotherapy on chronic sinusitis in children with allergy. Auris Nasus Larinx 1990; 17:33-38.
59. Sava G: Pharmacological aspects and therapeutic application of lysozymes. EXS 1996; 75:433-449.
60. Li-Chan E, Nakai S: Biochemical basis for the properties of egg white. Crit Rev Poult Biol 1989; 2:21-58.
61. Lichtenstein GR, Deren J, Katz S, Kennedy A, Ware JH: The Bowman Birk protease inhibitor: a novel therapy for treatment of patients with active ulcerative colitis. Gastroenterology 2002; 122:A-60.
62. Daddaoua A, Puerta V, Zarzuelo A y cols.: Bovine glycomacropeptide is anti-inflammatory in rats with hapten-induced colitis. J Nutr 2005; 135:1164-1170.
63. Aimutis WR: Bioactive properties of milk proteins with particular focus on anticariogenesis. J Nutr 2004; 134:989S-995S.
64. Xiao R, Badger TM, Simmen FA: Dietary exposure to soy or whey proteins alters colonic global gene expression profiles during rat colon tumorigenesis. Mol Cancer 2005; 4:1-17.
65. Kennedy RS, Konok GP, Bounous G, Baruchel S, Lee TD: The use of a whey protein concentrate in the treatment of patients with metastatic carcinoma: a phase I-II clinical study. Anticancer Res 1995; 15:2643-2649.
66. Hayes TG, Falchook GF, Varadhachary GR, Smith DP, Davis LD, Dhingra HM y cols.: Phase I trial of oral talactoferrin alfa in refractory solid tumors. Invest New Drugs 2005.
67. Ward PP, Paz E, Conneely OM: Multifunctional roles of lactoferrin: a critical overview. Cell Mol Life Sci 2005; 62:2540-2548.
68. Iigo M, Shimamura M, Matsuda E, Fujita K, Nomoto H, Satoh J y cols.: Orally administered bovine lactoferrin induces caspase-1 and interleukin-18 in the mouse intestinal mucosa: a possible explanation for inhibition of carcinogenesis and metastasis. Cytokine 2004; 25:36-44.
69. Mader JS, Salsman J, Conrad DM, Hoskin DW: Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines. Mol Cancer Ther 2005; 4:612-624.
70. Yoo YC, Watanabe R, Koike Y, Mitobe M, Shimazaki K, Watanabe S y cols.: Apoptosis in human leukemic cells induced by lactoferricin, a bovine milk protein-derived peptide: involvement of reactive oxygen species. Biochem Biophys Res Commun 1997; 237:624-628.
71. Friedman M, Brandon DL: Nutritional and health benefits of soy proteins. J Agric Food Chem 2001 Mar; 49(3):1069-1086.
72. Kennedy AR: Chemopreventive agents: protease inhibitors. Pharmacol Ther 1998; 78:167-209.
73. Armstrong WB, Kennedy AR, Wan XS, Tayor TH, Nguyen QA, Jensen J, Thompson W y cols.: Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin Cancer Res 2000; 6:4684-4691.
74. Armstrong WB, Wan XS, Kennedy AR, Taylor TH, Meyskens FL Jr: Development of the Bowman-Birk inhibitor for oral cancer chemoprevention and analysis of Neu immunohistochemical staining intensity with Bowman-Birk inhibitor concentrate treatment. Laryngoscope 2003; 113:1687-1702.
75. Malkowicz SB, Mckenna WG, Vaughn DJ, Wan XS, Propert KJ, Rockwell, K, Marks SH y cols.: Effects of Bowman-Birk inhibitor concentrate (BBIC) in patients with benign prostatic hyperplasia. Prostate 2001; 48:16-28.
76. Dittmann KH, Mayer C, Rodemann HP: Radioprotection of normal tissue to improve radiotherapy: the effect of the Bowman Birk protease inhibitor.Curr Med Chem Anticancer Agents 2003; 3:360-363.
77. Food and Drug Administration. food labeling:health claims; soy protein and coronary artery disease. Fed Regist 1999; 64:57699-57733.
78. The Nutrition Committee of the American Heart Association 2000 AHA Dietary Guidelines. Revision 2000: A statement for healthcare professionals from the nutrition committee of the American Heart Association. Circulation 2000; 102:2284-2299.
79. Costa RL, Summa MA: Soy protein in the management of hyperlipidemia. Ann Pharmacother 2000; 34:931-935.
80. Adams MR, Golden DL, Franke AA, Potter SM, Smith HS, Anthony MS: Dietary soy beta-conglycinin (7S globulin) inhibits atherosclerosis in mice. J Nutr 2004; 134:511-516.
81. Dewell A, Hollenbeck PL, Hollenbeck CB: A critical evaluation of the role of soy protein and isoflavone supplementation in the control of plasma cholesterol concentrations. J Clin Endocrin Metab 2006. In press.
82. FitzGerald RJ, Murray BA, Walsh DJ: Hypotensive peptides from milk proteins. J Nutr 2004; 134:980S-988S.
83. Meisel: Biochemical properties of regulatory peptides derived from milk proteins. Biopoly 1997; 43:119-128.
84. Lonnerdal B: Nutritional and physiologic significance of human milk proteins. Am J Clin Nutr 2003; 77:1537S-1543S.
85. Field CJ: The immunological components of human milk and their effect on imune development in infants. J Nutr 2005; 135:1-4.
86. Severin S, Wenshui X: Milk biologically active components as nutraceuticals: review. Crit Rev Food Sci Nutr 2005; 45:645-656.
87. Milani S, Calabro A: Role of growth factors and their receptors in gastric ulcer healing. Microsc Res Tech 2001; 53:360-371.
88. Palomino A, Hernández-Bernal F, Haedo W, Franco S, Mas JA, Fernández JA y cols.: A multicenter, randomized, doubleblind clinical trial examining the effect of oral human recombinant epidermal growth factor on the healing of duodenal ulcers. Scand J Gastroenterol 2000; 35:1016-1022.
89. Tsang MW, Wong WK, Hung CS, Lai KM, Tang W, Cheung EY, Kam G, Leung L, Chan CW, Chu CM, Lam EK: Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care 2003; 26:1856-1861.
90. Xiao X, Xiong A, Chen X, Mao X, Zhou X: Epidermal growth factor concentrations in human milk, cow's milk and cow's milk-based infant formulas. Chin Med J (Engl) 2002; 115:451-454.
91. Warner BW, Warner BB: Role of epidermal growth factor in the pathogenesis of neonatal necrotizing enterocolitis. Semin Pediatr Surg 2005; 14:175-180.
92. Jones MK, Tomikawa M, Mohajer B, Tarnawski AS: Gastrointestinal mucosal regeneration: role of growth factors. Front Biosci 1999; 4:D303-D309.
93. Hormi K, Cadiot G, Kermorgant S, Dessirier V, Le Romancer M, Lewin MJ y cols.: Transforming growth factor-alpha and epidermal growth factor receptor in colonic mucosa in active and inactive inflammatory bowel disease. Growth Factors 2000; 18:79-91.
94. Hauck AL, Swanson KS, Kenis PJ, Leckband DE, Gaskins HR, Schook LB: Twists and turns in the development and maintenance of the mammalian small intestine epithelium. Birth Defects Res C Embryo Today 2005; 75:58-71.
95. MacDonald TT, DiSabatino A, Gordon JN: Immunopathogenesis of Crohn's disease. JPEN J Parenter Enteral Nutr 2005; 29:S118-24.
96. Ford H, Watkins S, Reblock K, Rowe M: The role of inflammatory cytokines and nitric oxide in the pathogenesis of necrotizing enterocolitis. J Pediatr Surg 1997; 32:275-82.
97. Howarth GS: Insulin-like growth factor-I and the gastrointestinal system: therapeutic indications and safety implications. J Nutr 2003; 133:2109-12.
98. Clare DA, Swaisgood HE: Bioactive milk peptides: a prospectus. J Dairy Sci 2000; 83:1187-1195.